CYCC vs. CLVR, ARDS, BPTS, NBY, SXTP, ARAV, ATXI, ONCO, MBIO, and AGRX
Should you be buying Cyclacel Pharmaceuticals stock or one of its competitors? The main competitors of Cyclacel Pharmaceuticals include Clever Leaves (CLVR), Aridis Pharmaceuticals (ARDS), Biophytis (BPTS), NovaBay Pharmaceuticals (NBY), 60 Degrees Pharmaceuticals (SXTP), Aravive (ARAV), Avenue Therapeutics (ATXI), Onconetix (ONCO), Mustang Bio (MBIO), and Agile Therapeutics (AGRX). These companies are all part of the "pharmaceutical preparations" industry.
Cyclacel Pharmaceuticals (NASDAQ:CYCC) and Clever Leaves (NASDAQ:CLVR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, community ranking, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.
Cyclacel Pharmaceuticals has a net margin of 0.00% compared to Clever Leaves' net margin of -102.77%. Clever Leaves' return on equity of -63.32% beat Cyclacel Pharmaceuticals' return on equity.
In the previous week, Cyclacel Pharmaceuticals had 1 more articles in the media than Clever Leaves. MarketBeat recorded 7 mentions for Cyclacel Pharmaceuticals and 6 mentions for Clever Leaves. Cyclacel Pharmaceuticals' average media sentiment score of 0.24 beat Clever Leaves' score of 0.10 indicating that Cyclacel Pharmaceuticals is being referred to more favorably in the media.
Clever Leaves has higher revenue and earnings than Cyclacel Pharmaceuticals. Clever Leaves is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. Comparatively, 6.9% of Clever Leaves shares are held by institutional investors. 8.5% of Cyclacel Pharmaceuticals shares are held by insiders. Comparatively, 8.2% of Clever Leaves shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Cyclacel Pharmaceuticals has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500. Comparatively, Clever Leaves has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500.
Cyclacel Pharmaceuticals presently has a consensus target price of $11.00, indicating a potential upside of 450.00%. Given Cyclacel Pharmaceuticals' higher possible upside, equities research analysts plainly believe Cyclacel Pharmaceuticals is more favorable than Clever Leaves.
Cyclacel Pharmaceuticals received 174 more outperform votes than Clever Leaves when rated by MarketBeat users. However, 81.25% of users gave Clever Leaves an outperform vote while only 49.34% of users gave Cyclacel Pharmaceuticals an outperform vote.
Summary
Cyclacel Pharmaceuticals beats Clever Leaves on 10 of the 17 factors compared between the two stocks.
Get Cyclacel Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CYCC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CYCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cyclacel Pharmaceuticals Competitors List
Related Companies and Tools
